Show simple item record

dc.creatorMartin, James M.
dc.creatorHandorf, Elizabeth A.
dc.creatorMontero, Alberto J.
dc.creatorGoldstein, Lori J.
dc.identifier.citationJames M Martin, Elizabeth A Handorf, Alberto J Montero, Lori J Goldstein, Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data, The Oncologist, Volume 27, Issue 6, June 2022, Pages 441–446,
dc.description.abstractBackground: Metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (Her2−) breast cancer remains a significant cause of cancer-related mortality. First-line treatment with endocrine therapy (ET) with a cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has largely become the standard systemic therapy. Following progression, no prospective randomized data exist to help guide second-line treatment. Materials and Methods: This study used a nationwide electronic health record (EHR)-derived de-identified database, specifically analyzing 1210 patients with HR+/Her2− metastatic breast cancer (MBC) who were treated in the first-line setting with a CDK4/6i from the years 2015-2020. The aim of this study was to assess what therapies were given after first-line progression on CDK4/6i and to observe treatment patterns over time. Determination of second-line treatment efficacy, specifically assessing real-world progression-free survival (rwPFS) and overall survival (OS) was performed. Results: A total of 839 patients received a documented second-line therapy after progression on first-line CDK4/6i treatment. Chemotherapy was chosen for 29.7% of patients, and the use of chemotherapy decreased over time. Three hundred two (36.0%) of patients continued a CDK4/6i. Data were adjusted for age, race, Eastern Cooperative Oncology Group (ECOG) performance status, stage at breast cancer diagnosis, and insurance payer type. Continuation of the CDK4/6i was associated with improved rwPFS (HR 0.48, 95% CI 0.43-0.53, P < .0001) and OS (HR 0.30, 95% CI 0.26-0.35, P < .0001) compared to chemotherapy. A majority of these patients continued the same CDK4/6i in the second-line setting, as was given in the first-line setting. Conclusion: While prospective data are needed, analysis of real-world data suggests a survival benefit for continuation of a CDK4/6i beyond frontline progression for patients with HR+/Her2− MBC.
dc.format.extent6 pages
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartThe Oncologist, Vol. 27, Iss. 6
dc.relation.isreferencedbyOxford University Press (OUP)
dc.rightsAttribution CC BY
dc.subjectCDK4/6 inhibitor
dc.titleSystemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
dc.type.genreJournal article
dc.contributor.groupFox Chase Cancer Center (Temple University)
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.temple.creatorHandorf, Elizabeth A.
dc.temple.creatorGoldstein, Lori J.

Files in this item

HandorfEtAl-JournalArticle-202 ...

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY